NEW CHALLENGE TO CANCER AND LONGEVITY
Journal: Cardiometry
Year: 2022

“Saisei Mirai” has been focusing on cancer treatments and has developed several new treatments, including GcMAF (Gc protein-derived Macrophage Activating Factor) and oral MAF (Macrophage Activating Factor) which are immunotherapies developed by “Saisei Mirai”. We are collaborating with 6 universities here in Japan to develop new and better treatments mainly for cancer. At the same time, GcMAF and oral MAF showed good effects for many infectious agents, autism spectrum disorder (ASD), chronic fat